Radiotherapy for Prostate Cancer: When Is It Applied?

Prostate cancer, one of the most common malignancies in men, offers several effective therapeutic options, particularly when detected early. Radiotherapy has emerged as a leading treatment method, increasingly chosen as a primary approach not only for its oncological efficacy but also for its more favorable risk-benefit profile compared to surgery.

Radiotherapy employs ionizing radiation to damage the DNA of tumor cells, inhibiting their proliferation while striving to preserve surrounding healthy tissue. For prostate cancer, the most frequently used techniques include external beam radiotherapy, utilizing methods like Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT), and brachytherapy, which involves implanting radiation sources directly into or near the prostate.

This treatment is often recommended as a primary option for localized prostate cancer of low to intermediate risk, where radiation alone can be curative. It is also combined with hormone therapy for locally advanced disease. Furthermore, radiotherapy serves as a vital alternative for patients who are not candidates for surgery due to medical reasons, such as advanced age, comorbidities, or surgical risks. Many patients also consciously opt for radiation after consulting with oncologists and urologists, often due to its milder side effect profile.

A significant advantage of radiotherapy over surgery, especially for localized prostate cancer, lies in the long-term oncological outcomes, which are largely comparable. However, the difference in side effects significantly impacts quality of life. Urinary incontinence is considerably more common and severe after surgery, as the prostate's removal directly affects the mechanism controlling urination. Radiotherapy, by contrast, leaves this mechanism anatomically intact, resulting in a much lower incidence of permanent incontinence. Erectile dysfunction occurs with both treatments, but its onset differs: surgery leads to a more abrupt decline, while radiotherapy's effects develop gradually over months or years, allowing more time for adaptation and potential medical support.

Consequently, many patients facing oncologically equivalent options choose radiotherapy to minimize the risk of lasting urinary and sexual function issues. The final treatment decision is always individualized, made within a multidisciplinary team, considering the disease stage, the patient's overall health, and personal priorities. It is also important to note that for very low or low-risk prostate cancers, small, slow-growing tumors, active monitoring may be a suitable alternative to immediate treatment.